Santarus to Webcast Analyst Day and Investor Briefing Presentation on May 13
... Collaborating Center for Travelers' Health rifamycin SV MMX (R) - Clinical Development Program in Tr...lower GI product candidates, budesonide MMX(R) and rifamycin SV MMX(R) for the U.S. market. Budesonide MMX is ...on of mild or moderate active ulcerative colitis. rifamycin SV MMX has been investigated in a Phase II clinica...ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
WELLESLEY HILLS, Mass., Feb. 25 /PRNewswire/ -- Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, as a result of growing interest from prospective buyers, announced today a development strategy for further advancement of the company's proprietary benzoxazinor...Researchers find how some antibiotics kill bacteria
...robiology at Ohio State University. The antibiotics studied belong to the rifamycin family. Until now, researchers believed that these antibiotics and their de...lecular details help explain why bacteria that are resistant to one kind of rifamycin antibiotic might still be sensitive to another. "That may help to narrow...ActivBiotics' Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
...sale of ActivBiotics intellectual property assets for $3.5 million. The assets consisted of 1) Rifalazil, a Phase II antibiotic, 2) a library of novel rifamycin compounds, and 3) a clinical stage superoxide dismutase mimetic (SODm) and a library of SODm small molecules. Mr. Finn praised the team of ActivBiot...